Estudio comparativo de la eficacia hipotensora y de las variaciones en la amplitud de pulso ocular entre las combinaciones fijas dorzolamida/timolol y brinzolamida/timolol

Sánchez-Pulgarín, M.; Martínez-de-la-Casa, J.M.; Feijoó, Julián García; Sáenz-Francés, F.; Santos-Bueso, E.; Herrero-Vanrell, Rocı́o; Sánchez, Julián García

doi:10.1016/j.oftal.2011.01.006

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, membrane-associated CA activity within neuronal processes is also likely to modulate the pH of extracellular fluid, which can affect metabolic activity [106,113]. Additionally, ocular pulse amplitude increases following dorzolamide administration [114,115]. However, no changes were noted in ONH blood flow following dorzolamide administration in healthy human subjects [116].…”

Section: Carbonic Anhydrase Inhibitorsmentioning

confidence: 99%

Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action

Shih

Calkins²

2012

Expert Review of Ophthalmology

View full text Add to dashboard Cite

Primary open-angle glaucoma, a long-term degenerative ocular neuropathy, remains a significant cause of vision impairment worldwide. While many risk factors have been correlated with increased risk for primary open-angle glaucoma, intraocular pressure (IOP) remains the only modifiable risk factor and primary therapeutic target. Pharmacologic therapies are administered topically; these include α2-agonists, β-antagonists, prostaglandin analogs and carbonic anhydrase inhibitors. Some of these topical medications exhibit secondary neuroprotective effects independent of their effect on IOP. This review covers the possible mechanisms of neuroprotection stimulated by drugs currently marketed for the lowering of IOP, based on known literature. While the neuroprotective properties of many glaucoma pharmaceuticals are promising from an experimental standpoint, key challenges for the development of new clinical practices include unknown systemic side effects, limited methods of drug delivery to the retina and optic nerve, and development of extended-release formulations.

show abstract

Section: Carbonic Anhydrase Inhibitorsmentioning

confidence: 99%

Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action

Shih

Calkins²

2012

Expert Review of Ophthalmology

View full text Add to dashboard Cite

show abstract

Diuretics

Roberts¹,

Wallin²

2014

A Worldwide Yearly Survey of New Data in Adverse Drug Reactions and Interactions

View full text Add to dashboard Cite

Fixed topical combinations in glaucomatous patients and ocular discomfort

Nebbioso

Evangelista

Librando

et al. 2012

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

This work shows the better tolerability of brinzolamide 1% plus timolol 0.5% suspension, compared with dorzolamide 2% plus timolol 0.5% solution. Fortunately, some of the adverse reactions induced by preserved eye drop glaucoma medication are reversible after removing the preservatives. Both the potential for added benefit and patient compliance should be considered when selecting ocular hypotensive therapy.

show abstract

Estudio comparativo de la eficacia hipotensora y de las variaciones en la amplitud de pulso ocular entre las combinaciones fijas dorzolamida/timolol y brinzolamida/timolol

Cited by 3 publications

References 15 publications

Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action

Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action

Diuretics

Fixed topical combinations in glaucomatous patients and ocular discomfort

Contact Info

Product

Resources

About